Biomarker ID | 1524 |
PMID | 25170626 |
Year | 2014 |
Biomarker | Oligophrenin-1 (OPHN1) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) |
Odds Ratio/Hazard Ratio/Relative Risk | HR: Univariate Analysis: 2.361 (95% CI: 1.229–4.656); Multivariate Analysis: 2.372 (95% CI: 1.225–4.713) |
Effect on Pathways | Pathways include: Rho cell motility signaling pathway, RhoA activity regulation, Rho GTPase cycle, Signal transduction |
Experiment | Stage pT2 Vs Stage pT3 |
Type of Biomarker | Prognostic |
Cohort | 141 Prostate cancer samples were chosen for the analysis. 83 had Stage pt2 and rest had stage pT3 |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | univariate: p=0.0099; Multivariate: 0.0104 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |